RenovaCare Inc., a Roseland-based developer of patented technologies for stem cell regeneration, announced on Tuesday it has appointed seasoned biotech executive Robert W. Cook as its new chief financial officer and board secretary.
Cook, who has more than 20 years of experience in senior-level financial roles, most recently served as the CFO at CorMedix Inc., BioBlast Pharma Ltd. and Strata Skin Sciences. Previously, he served as interim president and CFO at Immune Pharmaceuticals and EpiCept Corp. and was the CFO of Pharmos Corp.
“Mr. Cook’s appointment marks the most recent addition in the accelerated build-out of our world-class executive management team for bringing RenovaCare regenerative cell spray therapies to market,” Alan L. Rubino, CEO and president, RenovaCare, said. “Bob brings extensive experience in leading top-tier financial transactions with innovative medical technologies, products, and therapies. I look forward to leveraging his industry-specific expertise, valuable to our planned business progression, including fund raising, partnerships, collaborations, financial compliance, and interfacing with our regulatory and clinical teams.”
Cook began his career in financial services at Chase Manhattan. He was also the vice president of the health care group at General Electric Capital Commercial Finance.
“RenovaCare has a robust technology portfolio, accomplished leadership team, and ample cash to accelerate its regenerative therapy program. I look forward to building shareholder value as we position the company for future commercial collaborations, financings, and regulatory initiatives,” Cook said.
